| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
PharmaLundensis AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.36 |
| 52 Week High | kr1.51 |
| 52 Week Low | kr0.16 |
| Beta | -0.31 |
| 1 Month Change | 0% |
| 3 Month Change | 1.69% |
| 1 Year Change | -44.62% |
| 3 Year Change | -63.64% |
| 5 Year Change | -90.58% |
| Change since IPO | -90.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHAL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 0.4% |
| 1Y | -44.6% | -4.8% | 11.4% |
Return vs Industry: PHAL underperformed the Swedish Biotechs industry which returned -3.2% over the past year.
Return vs Market: PHAL underperformed the Swedish Market which returned 8.6% over the past year.
Price Volatility
| PHAL volatility | |
|---|---|
| PHAL Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.5% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: PHAL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHAL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1 | Staffan Skogvall | www.pharmalundensis.se |
PharmaLundensis AB operates as a pharmaceutical company. The company develops Iodocarb for treating chronic obstructive pulmonary disease; and treatments for chronic bronchitis and influenza-induced lung failure. It develops EcoFilter, a system that eliminates the release of pharmaceutical drugs and multi-resistant bacteria in hospital wastewater.
PharmaLundensis AB Fundamentals Summary
| PHAL fundamental statistics | |
|---|---|
| Market cap | kr15.28m |
| Earnings (TTM) | -kr4.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs PHAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHAL income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr4.40m |
| Earnings | -kr4.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 163.1% |
How did PHAL perform over the long term?
See historical performance and comparison